Malignant Giant Cell Tumor of Bone: A Clinicopathological Analysis of 15 Cases.
5 affiliations
- 1Department of Pathology Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China shsmu.edu.cn.
- 2Department of Pathology The First People's Hospital of Yulin Guangxi China.
- 3Department of Pathology Guilin People's Hospital Guangxi China.
- 4Department of Pathology Pingyi County People's Hospital Linyi China.
- 5Shanghai Jiao Tong University School of Medicine Shanghai China shsmu.edu.cn.
Abstract
Malignant giant cell tumor of bone (MGCTB) refers to the presence of high-grade sarcomatous components within a giant cell tumor of bone (GCTB). MGCTB is classified into primary (PMGCTB) and secondary (SMGCTB) forms. It is extremely rare and often misdiagnosed as other sarcomas, especially when typical GCTB morphology is absent, leading to diagnostic pitfalls. In this study, we analyze 15 cases of MGCTB, reviewing clinical data, pathological features, immunohistochemistry, molecular characteristics, and follow-up outcomes. PMGCTB was found to be rarer than SMGCTB. Clinical symptoms predominantly include pain, mass detection, and restricted movement. MGCTB may lack GCTB components entirely, with malignant areas often presenting as high-grade sarcomas, though low-grade sarcomatous features can also be observed. Immunohistochemical markers such as H3.3G34W and H3G34W gene mutations exhibit high specificity and sensitivity for GCTB and MGCTB diagnosis. However, in cases with high dedifferentiation, few or absent mononuclear stromal cells may result in negative H3.3G34W expression and undetectable H3.3G34W gene mutations. The presence of high-grade sarcomatous morphology in a giant cell-rich tumor warrants thorough exclusion of PMGCTB. Additionally, misdiagnosis as SMGCTB can occur after denosumab treatment for GCTB. In conclusion, a comprehensive diagnostic approach combining patient age, tumor location, imaging, histology, immunohistochemistry, and molecular findings, with genetic testing when necessary, is essential for accurate diagnosis of GCTB and MGCTB. With a median follow-up of 12 months (range, 1-120 months), the 1-, 3-, and 5-year overall survival rates of the cohort were 76.9%, 76.9%, and 61.5%, respectively, and the median overall survival was not reached.
Related
- Giant Postpartum Ovarian Mixed Germ Cell Tumor Containing Mature Cystic Teratoma and Yolk Sac Tumor: A Case Report With Multimodality Imaging and Clinicopathological Correlation.
- Clinicopathological characteristics and prognostic value of Ki-67 in extremity tenosynovial giant cell tumor: a retrospective cohort study highlighting anatomical differences
- Two-Dimensional Plot of the Image Analysis of Ovarian Tumor Peritoneal Cytology Specimens to Distinguish Malignant from Negative Cases.
- Clinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB ‐amplified renal cell carcinoma: a comprehensive study of 15 cases
- Clinicopathological Analysis of 1,000 Cases of Head and Neck Squamous Cell Carcinoma With Special Emphasis on Histological Variants and p16 Expression.
BibTeX
@article{jiang2026malignant,
title = {{Malignant Giant Cell Tumor of Bone: A Clinicopathological Analysis of 15 Cases.}},
author = {Li Jiang and Jinmin Li and Yue Fan and Xiang Ling and Bin Mi and Benjamin Ka Seng Thong and Chaofu Wang and Binshen Ouyang},
journal = {Human mutation},
year = {2026},
month = nov,
doi = {10.1155/humu/2709232},
url = {https://europepmc.org/article/MED/42999439},
note = {CC BY},
}
RIS
TY - JOUR
TI - Malignant Giant Cell Tumor of Bone: A Clinicopathological Analysis of 15 Cases.
AU - Li Jiang
AU - Jinmin Li
AU - Yue Fan
AU - Xiang Ling
AU - Bin Mi
AU - Benjamin Ka Seng Thong
AU - Chaofu Wang
AU - Binshen Ouyang
PY - 2026
DA - 2026/11/06
JO - Human mutation
DO - 10.1155/humu/2709232
UR - https://europepmc.org/article/MED/42999439
AB - Malignant giant cell tumor of bone (MGCTB) refers to the presence of high-grade sarcomatous components within a giant cell tumor of bone (GCTB). MGCTB is classified into primary (PMGCTB) and secondary (SMGCTB) forms. It is extremely rare and often misdiagnosed as other sarcomas, especially when typical GCTB morphology is absent, leading to diagnostic pitfalls. In this study, we analyze 15 cases of MGCTB, reviewing clinical data, pathological features, immunohistochemistry, molecular characteristics, and follow-up outcomes. PMGCTB was found to be rarer than SMGCTB. Clinical symptoms predominantly include pain, mass detection, and restricted movement. MGCTB may lack GCTB components entirely, with malignant areas often presenting as high-grade sarcomas, though low-grade sarcomatous features can also be observed. Immunohistochemical markers such as H3.3G34W and H3G34W gene mutations exhibit high specificity and sensitivity for GCTB and MGCTB diagnosis. However, in cases with high dedifferentiation, few or absent mononuclear stromal cells may result in negative H3.3G34W expression and undetectable H3.3G34W gene mutations. The presence of high-grade sarcomatous morphology in a giant cell-rich tumor warrants thorough exclusion of PMGCTB. Additionally, misdiagnosis as SMGCTB can occur after denosumab treatment for GCTB. In conclusion, a comprehensive diagnostic approach combining patient age, tumor location, imaging, histology, immunohistochemistry, and molecular findings, with genetic testing when necessary, is essential for accurate diagnosis of GCTB and MGCTB. With a median follow-up of 12 months (range, 1-120 months), the 1-, 3-, and 5-year overall survival rates of the cohort were 76.9%, 76.9%, and 61.5%, respectively, and the median overall survival was not reached.
SN - 1059-7794
SN - 1098-1004
ER -